Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.
US-based gene-editing technology developer eGenesis closed a $125m series C round yesterday to further advance research conducted at Harvard University.
Spinout-focused investment firm Osage University Partners backed the round, as did Leaps by Bayer and Fresenius Medical Care Ventures, respective vehicles for pharmaceuticals and chemicals producer Bayer and for kidney dialysis centres operator Fresenius Medical Care.
Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus and Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, Arch Venture Partners, Wellington Partners, Khosla Ventures and Alta Partners also participated.
Founded in 2015, eGenesis is working on gene-editing and genome-engineering technologies to create human-compatible organs, tissues and cells from those harvested from animals – a process known as xenotransplantation.
The spinout is initially focused on kidney and islet cell transplants, and it will use the series C financing to move its lead assets in these two…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
